Signal Transduction Pathways Mediated by Secreted and Non-secreted Forms of intact Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) and its 1-97 N-terminal Fragment in PC-3 Human Prostate Cancer Cells

Hanief M Shahjee1,*, Benjamin Kefas2, Nisan Bhattacharyya1, and Mohamed K Radwan4
1Diabetes Branch, NIDDK, National Institutes of Health, Bldg 10-Room 8D12, 9000 Rockville Pike, MSC 1758, Bethesda, MD 20892, USA
2Division of Neuro-Oncology, Neurology Department, University of Virginia Health System, Charlottesville, Virginia 22908, USA
3Diabetes Branch, NIDDK, National Institutes of Health, Bldg 10-Room 8D12, 9000 Rockville Pike, MSC 1758, Bethesda, MD 20892, USA
4Department of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, New York 14642, USA

Abstract

Our previous results indicated that both the secreted and the intracellular form of full length and 1-97 N-terminal fragment of IGFBP-3 induces apoptosis in PC-3 human prostate cancer cells in an IGF-dependent and independent manner. This study was undertaken to delineate possible downstream signaling pathways that are involved in this process. Intact IGFBP-3 and its N-terminal 1-97 fragments with or without a signal pro-peptide was fused to YFP and expressed in PC-3 human prostate cancer cells. In some cases, the putative IGF-binding site present in full length IGFBP-3 and its N-terminal fragment was also mutated. Extent of apoptosis was quantified using FACS. Up-regulation of total Stat-1 and activation of phospho-Stat-1 was shown by western blot. TGF-β signal was measured by luciferase reporter assay. Results from inhibitor studies indicated that both the Caspase 8 and caspase 9 pathways are involved in IGFBP-3 (non-secreted form) induced apoptosis in PC-3 cells. Exogenous addition of IGFBP-3 to PC-3 cells increased Stat-1 protein expression/tyrosine phosphorylation. Interestingly, results also showed that knockdown of Stat-1 by siRNA potentiated the IGFBP-3 induced apoptosis in PC-3 cells. In addition, both full-length IGFBP-3 and its 1-97 N-terminal fragments inhibited TGF-β signaling in these cells. This is the first report that compares the signal transduction pathways involved in apoptotic actions of IGFBP-3 in PC-3 cells. Non-secreted form of full length IGFBP-3 and its N-terminal fragments induced apoptosis in PC-3 cells via activation of caspase 8 and caspase 9. We noted that both secreted and non-secreted forms of IGFBP-3 are involved in modulating Stat-1 and TGF-β pathways to induce apoptotic actions in PC-3 cells. Surprisingly, only non-secreted form of IGFBP-3 and its N-terminal fragments are involved in the induction of apoptosis in PC-3 cells via caspase 8 and caspase 9 activation. These studies clearly demonstrate

*hanief_shahjee@urmc.rochester.edu.

Present address: 1*Department of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, New York 14642, USA. Phone: (585) 275-1324, FAX: (585) 275-6007, hanief_shahjee@urmc.rochester.edu, 2Skeletal Clinical Studies Unit, CSDB, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA

Authors’ contributions
HMS carried out all experiments for these studies. NB supervised the research and interpretation of the data was carried out by HMS and NB. HMS, BK, NB and MKR made the final draft for the paper.
that secreted and non-secreted FL and its 1-97 N-terminal fragments induce apoptosis in PC-3 cells by regulating different mechanistic pathways

Keywords
N-terminal fragment; Apoptosis; Caspases; Human prostate cancer cells

1. Introduction

Insulin-like growth factor binding protein-3 (IGFBP-3), the most abundant of the six IGFBPs, is an important modulator of insulin-like growth factor (IGF) biological activity. IGFBP-3 binds to IGF-I and IGF-II with high affinities and restricts their bioavailability by forming stable ternary complexes with an acid-labile subunit. These complexes have been reported to be stable in plasma [1]. These complexes play major roles by preventing the IGFs from activating IGF-I receptors on target cells and stimulating cell proliferation and survival [2, 3]. Several reports have indicated that IGFBP-3 induces cell death and inhibits cell proliferation in various cell types, including prostate cancer cells (PC-3 cells), independent of its IGF-I binding [4–6]. IGFBP-3 is a secreted protein but it can be internalized to the nucleus when added to cells. Other reports have indicated that the presence of IGFBP-3 in the cytoplasm [5,7] or in the mitochondria [8] can induce cell death. Although the IGFBP-3 receptor(s) has not been identified, several signal transduction mechanisms responsible for biological actions of IGFBP-3 have been implicated [9,10,11,12]. IGFBP-3’s availability to cells and tissues is also regulated by proteolysis. Proteolysis of IGFBP-3 protein was initially demonstrated in serum of pregnant women, where it circulates primarily in low molecular weight forms [13]. These fragments bind to IGF with lower affinities, thereby increasing the limited availability of IGF to target receptors. Interestingly, various IGFBP-3 fragments have been reported to mediate direct stimulatory or inhibitory actions at the target cells [14].

Results from our previous study have demonstrated that when full-length IGFBP-3 is added exogenously to PC-3 cells, it can be processed into a small N-terminal fragment (amino acids 1-97). Our results also demonstrated that expression of 1-97 N-terminal IGFBP-3 fragments induces apoptosis in these cells [15]. Irrespective of the presence of a signal peptide, expression of either the wild-type intact IGFBP-3 and N-terminal 1-97 fragment or an IGF-nonbinding mutant 6m (mutations in six IGF-binding amino acid residues) fusion proteins caused a loss of cell viability indicative of apoptosis. However, the signal transduction mechanisms specific to either the full-length or the 1-97 N-terminal fragment of IGFBP-3 have not been studied.

In this study, not only we confirmed the involvement of secreted as well as non-secreted forms of IGFBP-3 in inducing apoptosis in PC-3 cells but we also studied the possible signaling pathways modulated by these various forms of IGFBP-3 during the process. We examined the induction of apoptosis in the presence or absence of caspase-8 and -9 inhibitors. Surprisingly, we found that intracellular form of intact and 1-97 N-terminal fragments of IGFBP-3 (wild-type or mutant) could induce apoptosis in a caspase-8 and -9 dependent manner in comparison to secreted form of IGFBP-3. Our results also demonstrate that exogenous addition of IGFBP-3 up-regulates Stat-1 protein levels and its tyrosine phosphorylation in a time-dependent fashion. To better understand the role of STAT-1 in IGFBP-3 induced apoptosis in PC-3 cells, we knocked down the Stat-1 expression by using STAT-1 siRNA technique in PC-3 cells. In contrast to a previous report [10], our results (Figure 1) showed that STAT1 siRNA treatment further potentiates IGFBP-3 (secreted and non-secreted) induced apoptosis in these cells thereby suggesting that Stat-1 may be an

J Cancer Ther. Author manuscript; available in PMC 2013 November 21.
important target molecule for IGFBP-3 induced PC-3 cell death. In addition, when we transfected a PC-3 stable cell line expressing CAGA-TGF-β reporter luciferase gene with various IGFBP-3 constructs (Figure 2), we observed that both secreted as well as non-secreted forms of IGFBP-3 constructs inhibited TGF-β signal in these cells, thereby providing evidence that IGFBP-3 also exploits the TGF-β signaling pathways for its apoptotic action in PC-3 cells.

2. Materials and Methods

2.1. Materials

The caspase 8-selective inhibitor Z-IETD-fmk, the caspase 9-selective inhibitor Z-LEHD-fmk, and annexin V-APC were purchased from BD Pharmingen (San Diego, CA). Recombinant glycosylated human IGFBP-3 was obtained from R&D Systems (Minneapolis, MN). Lipofectamine Plus transfection reagent was obtained from Invitrogen (Carlsbad, CA). TGF-β and mouse β-actin antibody were purchased from Sigma Aldrich (St Louis, MO). Stat-1 siRNA was purchased from Dharmacon (Lafayette, CO). Rabbit anti-human antibodies against total and tyrosine phosphorylated (Y701) Stat-1 proteins were obtained from Cell Signaling Technology (Danvers, MA).

2.2. Transfection

PC-3 cells (1.5 × 10^5 cells/6-well) were grown to 70–80% confluence in F12K medium containing 10% fetal bovine serum (FBS). Cells were transfected (37 °C, 3 h) in 1 ml of serum-free medium containing 500ng of different plasmid constructs using Lipofectamine Plus (Invitrogen). The cells were recovered by adding 1.7 ml of F12K medium containing 0.3 ml of FBS and were incubated at 37 °C for 48 h unless otherwise specified.

2.3. Whole cell extract preparation

PC-3 cells were incubated with noted concentrations of recombinant IGFBP-3 (R & D Systems, Minneapolis, MN) for indicated periods. After incubation, cells were washed with phosphate-buffered saline (PBS) and were lysed with 100 μl per 20-μl cell pellet of whole cell extract buffer (10 mM HEPES, pH 7.4, 10% glycerol, 250 mM NaCl, 1 mM EDTA, 0.1% Nonidet P-40, 1 mM dithiothreitol, and 1x protease inhibitor mixture) at 4 °C for 20 min. Lysates were vortexed at high speed for 15 s and placed on ice for 5–10 min. After centrifugation (12,000 rpm, 5 min, 4 °C), whole cell extracts (supernatants) were stored at −70 °C.

2.4. Western blot

Protein concentrations were measured using the DC protein assay (Bio-Rad). Proteins were fractionated using 4–20% SDS-PAGE (Bio-Rad) under reducing conditions. For whole cell extracts, 50 μg of protein was loaded per lane. Specific proteins were identified by western blotting using Rabbit anti-Stat-1 antibody or Rabbit pStat-1 antibody (Cell Signaling Technology, Danvers, MA). Equal loading of the protein was confirmed by using mouse anti-human β-actin antibody (Sigma, St. Louis, MO). Protein bands were detected by using SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL).

2.5. siRNA Transfection

PC-3 cells were plated in antibiotic-free F12K medium (1.0 × 10^5 cells/ml for 12-well plate) for transfection. Cells were transfected with either Stat-1, non-target or scrambled siRNA following a procedure provided by the supplier (Dharmacon). Cells were incubated for 24–96 h for protein analysis. For cell-death analysis experiments, cells were first transfected with STAT-1 siRNA or scrambled siRNA for 24 h and then were transfected with the
indicated IGFBP-3 constructs in serum-free media for 3h and incubated in serum containing media for 48 h for FACS analysis.

2.6. Fluorescence activated cell sorting (FACS) analysis

After transfecting PC-3 cells with IGFBP-3 constructs for 3 hrs, 20 μM each of caspase 8 and caspase 9 inhibitor was added before cells were incubated at 37 °C in serum containing media for recovery. For analysis of apoptosis, both attached and floating cells were collected. The cell pellets were washed with 1x binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl₂) (BD Pharmingen, San Diego, CA) and were stained using 300–500 μl of binding buffer containing 5 μl of annexin V-APC at room temperature for 15–30 min. Cells were analyzed using a CyAn LX flow cytometer equipped with Summit software (DakoCytomation, Fort Collins, CO).

2.7. Luciferase reporter assay

PC-3 cells were transfected with the TGF-β-responsive reporter construct (CAGA)12 tk luc plasmid DNA for 3 hrs. Cells were recovered in serum-containing media and cells were incubated for overnight at 37 °C. Selective marker G418 was added and cells that stably expressed this construct were selected after 3 weeks of incubation with G418. One of the stable cell (CAGA-11) was transiently transfected with YFPN1, PrewtFL, Prewt(1-97), Pre6m(1-97), WTFL, WT (1-97), and 6m(1-97) along with Renilla luciferase construct (transfection control) for 3 h followed by the recovery in 10% serum containing F12K media for 24 h. Cells were washed and TGF-β (10ng/ml) was added to fresh serum-free media overnight at 37°C. Cells were washed, lysed and luciferase assay was performed using a dual luciferase assay system (Promega, Madison, WI). Luciferase activities were normalized by using renilla luciferase amounts present in each extract.

2.8. Statistical analysis

All data were presented as means ± standard deviation (SD). The significance of the difference between mean values was determined by an analysis of variance with p < .05 considered significant.

3. Results

3.1. Addition of inhibitors specific for caspase-8 and caspase-9 reduces IGFBP-3-induced apoptosis in PC-3 cells

Results from our previous study demonstrated that the expression of various IGFBP-3 fusion protein constructs induced apoptosis in PC-3 cells. [5,15]. In order to understand the mechanism(s) by which full-length IGFBP-3 and its N-terminal 1-97 fragment induce apoptosis, we transfected PC-3 cells with various IGFBP-3 constructs with or without a signal peptide. Apoptosis was determined in untreated cells (red bars) and in the presence of 20 μM of caspase-8 (IETD; yellow bars) and 20 μM of caspase-9 (LEHD; green bars) specific inhibitors. The number of apoptotic cells was determined by Annexin-V staining (FACS). Results indicated that the addition of either caspase 8 or 9 inhibitor significantly inhibited IGFBP-3-induced apoptosis in PC-3 cells (Figure 1). These results clearly shows that intracellular form of full length and 1-97 N-terminal fragments of WT and 6m IGFBP-3 induce apoptosis in PC-3 cancer cells using both caspase-8 and caspase-9 pathway which is not the case with secreted form of Intact and 1-97 N-terminal fragment of IGFBP-3. These results also confirm that IGFBP-3 does not need to depend on the availability of IGF or be secreted to induce apoptosis in PC-3 cells and interestingly secreted form of IGFBP-3 is not involved in inducing apoptosis via caspase 8 and caspase 9 activation pathways.
3.2. Addition of exogenous IGFBP-3 increases the expression of Stat-1 protein level and its tyrosine phosphorylation (Y\textsuperscript{701}) in PC-3 cells

A previous report [10] has shown that the addition of IGFBP-3 induces apoptosis and differentiation via STAT-1 in rat chondroprogenitor cells. In order to investigate the roles of STAT-1 signaling pathways in IGFBP-3 induced apoptosis in PC-3 cells, we incubated the cells with different concentrations of exogenous recombinant IGFBP-3. Expression of total Stat-1 levels in PC-3 cells were increased in a dose-dependent manner, peaking after 50ng/ml of IGFBP-3 (Figure 2A) addition. There was also a transient increase in tyrosine-phosphorylated Stat-1 (pY\textsuperscript{701} STAT-1) levels within 10 min of incubation with 50ng of IGFBP-3 (Figure 2B). These results demonstrate that addition of IGFBP-3 can elevate the expression levels as well as pY\textsuperscript{701} Stat-1 in PC-3 cells indicating the involvement of Stat-1 signaling pathways.

3.3. Introduction of Stat-1 siRNA potentiates the IGFBP-3-induced apoptosis in PC-3 cells

In order to better understand the roles of STAT-1 signaling pathways in IGFBP-3 induced apoptosis in PC-3 cells, we first tested the effectiveness of a siRNA to block the expression of Stat-1 in these cells. Western blot analysis showed marked decrease in Stat-1 protein levels after 48 and 72 h of siRNA transfection in PC-3 cells (lanes marked as Stat-1 siRNA) compared to cells with no siRNA treatment or transfected either with a scrambled siRNA or a non-target siRNA (Figure 3A). There was also a significant decrease in Stat-1 mRNA levels after 24 hrs of siRNA transfection in PC-3 cells (data not shown) Secondly, cell viability was determined in PC-3 cells transfected first with either STAT-1 siRNA (black bars) or a scrambled siRNA (white bars) and then with full length and various 1-97 N-terminal IGFBP-3 constructs. FACS analysis results showed that the IGFBP-3-induced apoptosis was potentiated in cells transfected with Stat-1 siRNA (Figure 3B.), a result that is in contradiction with a previous observation [10] but this report confirms that Stat-1 plays an important role in IGFBP-3 induced apoptosis in PC-3 cells.

3.4. Expression of intracellular IGFBP-3 constructs inhibits TGF-β signaling in PC-3 cells

TGF-β has been implicated in several cellular processes including apoptosis and proliferation [16,17]. In order to determine and delineate the involvements of TGF-β signaling pathways, we compared the effects of intact IGFBP-3 or its N-terminal 1–97-IGFBP-3-YFP fragments in PC-3 cells. First, several PC-3 cell-lines that stably expressed (CAGA) 12 tk-luc construct, a TGF-β-responsive luciferase reporter system, were created. One of these clonal cell-lines was selected for transfection with various constructs (WTFL IGFBP-3/1-97 N-terminal fragment and 6m FL IGFBP-3/1-97 N-terminal fragment) that express IGFBP-3 with or without its signal peptide.Extent of TGF-β signals were measured by luciferase output with without the addition of TGF-β. There was significant inhibitions of TGF-β mediated (CAGA) 12 luciferase activities in cells transfected with YFP-WT-FL-IGFBP-3, YFP-WT-1–97-IGFBP-3, or Pre-WT-1–97-IGFBP-3-YFP in comparison to cells transfected with YFP empty vector or untransfected control (Figure 4). Similar results were observed with YFP-6m-1–97-IGFBP-3 and Pre-6m-1–97-IGFBP-3-YFP in which the IGF-binding site had been mutated, indicating that the inhibition of TGF-β signaling occurs through an IGF-independent mechanism. Interestingly, cells transfected with Pre-WT-FL-IGFBP-3-YFP had a little effect. Whole cell extracts and media collected from these transfected cells were examined and equivalent expression of IGFBP-3 fusion protein was observed in each sample (data not shown). Full-length IGFBP-3 as well as its 1-97 N-terminal fragment that expressed only intracellular protein inhibited TGF-β signaling in PC-3 cells. This indicates that TGF-β signaling pathways are involved in cellular actions of IGFBP-3.
4. Discussion

IGFBP-3, the most abundant IGFBP in human serum, acts not only as a carrier of IGFs prolonging their half-lives in circulation, but also functions as a modulator of IGF activity by regulating their availability to interact with IGF receptors [18]. However, there is increasing evidence that IGFBP-3 may have its own biological actions. For example, IGFBP-3 can inhibit cell proliferation in an IGF-independent manner [4,19,20]. Conceptually, IGFBP-3 can exert its actions on target cells by: (a) inducing apoptosis, (b) regulating cell cycle and proliferation, and (c) inducing cross-talk with major signal transduction pathways. Mechanisms for inducing apoptosis, in part, have been demonstrated by studies showing that IGFBP-3 increases the ratio of pro-apoptotic to anti-apoptotic proteins in breast cancer cells [21]. As a regulator of the cell cycle, IGFBP-3 has been shown to modulate the induction of the cyclin-dependent kinase inhibitory protein p21/WAF/CIP1 in LNCaP prostate cancer cells [22].

Previous studies demonstrated that caspase-8 can activate caspase-3 and -7 directly and/or through triggering the activation of caspase-9 by the release of mitochondrial cytochrome c [23]. Consistent with our previous studies [5], current data suggest that non-secreted IGFBP-3 induced apoptosis in PC-3 cells, is mediated by caspase-8 as well as the caspase-9 pathways (Figure 1). Our results indicate that apoptosis induced by non-secreted IGFBP-3 as compared to secreted form could be blocked after addition of caspase-8 and -9 inhibitors, indicating that both initiator caspase pathways are involved in this process.

Several studies have demonstrated that full-length IGFBP-3 can induce various signaling pathways (6,17,24,25). In this regard, PC-3 cells were transfected with different IGFBP-3 constructs and then treated with inhibitors specific for PI-3K and p38 MAPK. Results from FACS analyses indicated that there was little or no difference in the extent of cell death (data not shown) indicating that the PI-3K and p38 MAPK signaling pathways may not be involved in IGFBP-3 mediated cell death in PC-3 cells.

Another signaling molecule (Stat-1) has been implicated in IGFBP-3 induced apoptosis in rat chondroprogenitor cells [10], this study led us to demonstrate the role of Stat-1 in IGFBP-3 induced apoptosis in PC-3 human prostate cancer cells. Dose response experiment showed increased Stat-1 protein expression at higher concentrations of exogenous IGFBP-3. Tyrosine phosphorylation of Stat-1 was also enhanced at higher concentrations of exogenous IGFBP-3 in a time dependent manner (Figures 2a and 2b). In contrast to this previous report, our results indicated that STAT-1 knock-down potentiated the apoptotic effects of various IGFBP-3 constructs in PC-3 human prostate cancer cells (Figures 3a and 3b). This data suggests that Stat-1 protein might be playing a protective role in PC-3 cells and also suggesting that the involvement of STAT-1 in apoptosis and proliferation might be cell type dependent.

IGFBP-3 has shown to interact with transforming growth factor-β (TGF-β) cell surface receptors. In mink lung epithelial cells and other cell-types, IGFBP-3 binds to TGF-β receptor type V (TGF-βRV) [12]. An IGFBP-3 mediated inhibitory effect on growth involving this particular receptor has been proposed, but mechanisms of action have not been fully elucidated. In this pathway, IGFBP-3 also binds to and activates intracellular signaling via the TGF-βRII and TGF-βRI heteromeric complex [24,25]. Addition of IGFBP-3 activated Smad2 phosphorylation and inhibited cell growth in these cells. Studies have also indicated that the addition of TGF-β can potentiate IGFBP-3-induced cell death in PC-3 cells (6). In that regard, our results demonstrated that the expression of IGFBP-3 constructs could significantly inhibit TGF-β signaling pathways. It is also interesting to note that this inhibition was more prominent in cells where IGFBP-3 is expressed intracellularly.

J Cancer Ther. Author manuscript; available in PMC 2013 November 21.
Results from our previous studies [5,15] clearly indicated that the IGFBP-3-YFP fusion proteins expressed from Pre wt 1-97, Pre6m 1-97 WtFL, Wt 1-97, and 6m 1-97 constructs are present predominantly inside the cells whereas Prewt FL protein was present outside in the media. How these intracellular proteins can interfere with TGF-\(\beta\) signaling are not clear yet. Although we did not measure differential Smad activation levels in these cells, our data clearly suggest that TGF-\(\beta\) signaling pathways are playing an important role in IGFBP-3 induced biological actions in these cells. Future studies would be needed to elucidate the roles of IGFBP-3 in TGF-\(\beta\) signaling by comparing the gene and protein expression profile in these cells. Our data indicates that full length IGFBP-3 and its N-terminal fragments induced the apoptosis of PC-3 cells through the modulations of caspases 8, 9, STAT-1 and TGF-\(\beta\) signaling pathways are also involved. It also suggests the modulation of STAT-1 and TGF-\(\beta\) pathways as possible therapy for prostate cancer.

Acknowledgments

We gratefully acknowledge Drs. William Chong (NIDCR, NIH) and Maria Mochin-Peters (University of Maryland, Baltimore) for comments and suggestions.

This work was supported by an intramural grant from NIDDK, NIH.

References

1. Laursen T, Flyvbjerg A, Jorgensen JOL, Baxter RC. Stimulation of the 150-Kilodalton Insulin-Like Growth Factor-Binding Protein-3 Ternary Complex by Continuous and Pulsatile Patterns of Growth Hormone (GH) Administration in GH-Deficient Patients. Journal of Clinical Endocrinology and Metabolism. 2000; 85:4310–4314. [PubMed: 11095473]
2. Rechler MM, Clemmons DR. Regulatory actions of Insulin-like growth factor-binding proteins. Trends Endocrinology Metabolism. 1998; 9:176–183.
3. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocrinology Review. 2002; 23:824–854.
4. Hong J, Zhang G, Dong F, Rechler MM. Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. Journal of Biological Chemistry. 2002; 277:10489–10497. [PubMed: 11784719]
5. Bhattacharyya N, Pechhold K, Shahjee H, et al. Non-secreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus. Journal of Biological Chemistry. 2006; 281:24588–24601. [PubMed: 16793770]
6. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. Journal of Biological Chemistry. 1997; 272:12181–12188. [PubMed: 9115291]
7. Butt AJ, Fraley KA, Firth SM, Baxter RC. IGF-binding protein-3-induced growth inhibition and apoptosis do not require cell surface binding and nuclear translocation in human breast cancer cells. Endocrinology. 2002; 143:2693–2699. [PubMed: 12072403]
8. Lee KW, Ma L, Yan X, et al. Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor independent nucleo-mitochondrial translocation of RXRalpha/Nur77. Journal of Biological Chemistry. 2005; 280:16942–16948. [PubMed: 15731112]
9. Schedlich LJ, Young TF, Firth SM, Baxter RC. Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. Journal of Biological Chemistry. 1998; 273:18347–18352. [PubMed: 9660801]
10. Spagnoli A, Torello M, Nagalla SR, et al. Identification of STAT-1 as a molecular target of IGFBP-3 in the process of chondrogenesis. Journal of Biological Chemistry. 2002; 277:18860–18867. [PubMed: 1186859]
11. Zappalà G, Rechler MM. IGFBP-3, hypoxia and TNF-alpha inhibit adiponectin transcription. Biochemical and Biophysical Research Communication. 2009; 382:785–789.
12. Leal SM, Huang SS, Huang JS. Interactions of high affinity insulin-like growth factor-binding proteins with the type V transforming growth factor-beta receptor in mink lung epithelial cells. Journal of Biological Chemistry. 1999; 274:6711–6717. [PubMed: 10037769]

13. Giudice LC, Farrell EM, Pham H, et al. Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity. Journal of Clinical Endocrinology & Metabolism. 1990; 71:806–816. [PubMed: 1698200]

14. Angelloz-Nicoud P, Lalou C, Binoux M. Prostate carcinoma (PC-3) cell proliferation is stimulated by the 22-25-kDa proteolytic fragment (1-160) and inhibited by the 16-kDa fragment (1-95) of recombinant human insulin-like growth factor binding protein-3. Growth Hormone & IGF Research. 1998; 8:71–75. [PubMed: 10990447]

15. Shahjee H, Bhattacharyya N, Zappala G. An N-terminal fragment of insulin-Like growth factor binding protein-3 (IGFBP-3) induces apoptosis in human prostate cancer cells in an IGF-independent manner. Growth Hormone & IGF Research. 2008; 18:188–197. [PubMed: 17959403]

16. Oh Y, Muller HL, NGL, Rosenfeld RG. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. Journal of Biological Chemistry. 1995; 270:13589–13592. [PubMed: 7539790]

17. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta 2-induced growth inhibition in human breast cancer cells. Cancer Research. 1996; 56:1545–1550. [PubMed: 8603400]

18. Devi GR, Graham DL, Oh Y, Rosenfeld RG. Effect of IGFBP-3 on IGF and IGF-analogue-induced insulin-like growth factor-I receptor (IGFIR) signalling. Growth Hormone & IGF Research. 2001; 11:231–239. [PubMed: 11735239]

19. Lalou C, Lassarre C, Binoux M. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology. 1996; 137:3206–3212. [PubMed: 8754741]

20. Colston KW, Perks CM, Xie SP, Holly JM. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. Journal of Molecular Endocrinology. 1998; 20:157–162. [PubMed: 9513092]

21. Butt AJ, Firth SM, King MA, Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. Journal of Biological Chemistry. 2000; 275:39174–39181. [PubMed: 10998426]

22. Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates p1 alpha, 25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. Journal of Urology. 2001; 165:1319–1324. [PubMed: 11257709]

23. Green DR. Apoptotic pathways: the roads to ruin. Cell. 1998; 94:695–698. [PubMed: 9753316]

24. Fanayan S, Firth SM, Butt AJ, Baxter RC. Growth inhibition by insulin-like Growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta) and the type II TGF-beta receptor. Journal of Biological Chemistry. 2000; 275:39146–39151. [PubMed: 10993898]

25. Fanayan S, Firth SM, Baxter RC. Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-beta 1 signaling. Journal of Biological Chemistry. 2002; 277:7255–7261. [PubMed: 11751851]
Figure 1. IGFBP-3 induced apoptosis in PC-3 cells is inhibited by inhibitors specific for Caspase-8 and Caspase-9

PC-3 cells were transfected with plasmid constructs directing the expression of either the full-length IGFBP-3 or its N-terminal 1-97 fragments. Cells were subsequently treated with either DMSO (vehicle; Red bars) or 10 μM IETD (caspase-8 inhibitor; yellow bars) and LEHD (caspase-9 inhibitor; green bars) for 48 h. Results from FACS analyses (Annexin-V+ cells) are shown. Percentages of non-viable cells are indicated. Fig 1 showed significant inhibition of IGFBP-3 induced apoptosis in PC-3 cells in the presence of caspase-8 and/or caspase-9 inhibitors. Experiments were performed in triplicate twice and error bars represent mean ± SEM.
Figure 2. Addition of exogenous IGFBP-3 induced Stat-1 protein expression as well as its tyrosine phosphorylation (pY701) in PC-3 cells

(a) PC-3 cells were treated with exogenous recombinant IGFBP-3 (ng/ml are indicated below in each lane) for 1 h. Whole cell extracts were prepared and a western blot analysis was performed. Anti-human Stat-1 antibody was used to examine the Stat-1 protein (91 kDa) (upper panel) and β-actin (42 kDa) (lower panel) expression levels in each sample. There is a dose-dependent increase of Stat-1 protein expression level in the presence of exogenously added recombinant IGFBP-3. This data is a representative result of three independent experiments.

(b) IGFBP-3 treatment causes transient increase in Stat-1 tyrosine phosphorylation (pY701) PC-3 cells were treated with 50ng/ml of IGFBP-3 for indicated periods of time. Whole cell extracts were prepared and western blot was performed by using an antibody against pY701 STAT-1 (upper panel; indicated by a 91 kDa) (upper panel) and unmodified STAT-1 (middle panel, 91 kDa). The experiment was repeated three times. The blot was stripped and was reused to detect for the β-actin (lower panel; indicated by a 42 kDa protein) level using an anti-human β-actin antibody and that served as the loading control. Blot is a representative result of three independent experiments.
Figure 3. siRNA knockdown of Stat-1 protein in PC-3 cells
(a) Stat-1 protein expression levels were reduced after transfection with Stat-1 siRNA. PC-3 cells were transfected with no DNA (Untreated; Lane 1), scrambled siRNA (Lane 2), non-target (NT) siRNA (lane 3), and Stat-1 siRNA (Lane 4) for 24, 48, and 72 h. Whole cell extracts were prepared and western blot analyses were performed to examine the Stat-1 protein expression levels by using an anti-human Stat-1 antibody. Stat-1 protein expression level is decreased after 48 and 72 h of transfection. Blot is representative result of three independent experiments. Transfection of Stat-1 siRNA potentiates IGFBP-3-mediated apoptosis in PC-3 cells. (b) PC-3 cells were first transfected with either scrambled (open bars) or Stat-1 siRNA (black bars) for 24 h and subsequently with various constructs expressing the full-length and/or N-terminal fragments of IGFBP-3 protein for another 48 h (total 72 h). Results from FACS analyses are shown. Percentages of non-viable cells are indicated. Each experiment was performed in duplicate on three separate occasions. Data is expressed as mean ± SEM.
Figure 4. Transient transfection of IGFBP-3 constructs reduces TGF-β signaling in PC-3 cells

PC-3 cell-line stably expressing (CAGA) 12 tkluc (a TGF-β-responsive promoter construct) was used for this experiment. These cells were transfected with the indicated IGFBP-3 constructs and were subsequently treated with TGF-β (10 ng/ml) or carrier for 24 h. Dual luciferase (renilla luciferase was used as the transfection control) assays were performed. Fold activation (luciferase activity) values (+/− TGF-β added) obtained for each sample are shown. There is decreased TGF-β signaling in cells transfected with constructs that are expressing intracellular full-length and N-terminal 1-97 IGFBP-3. Each experiment was repeated three times in triplicates. Data is expressed as mean ± SEM.